News

The average one-year price target for Calliditas Therapeutics AB (NasdaqGS:CALT) has been revised to 42.86 / share. This is an increase of 5.27% from the prior estimate of 40.71 dated January 18, 2024.

The price target is an average of many targets provided by analysts. The latest targets range from a low of 24.20 to a high of 60.38 / share. The average price target represents an increase of 112.06% from the latest reported closing price of 20.21 / share.

What is the Fund Sentiment?

There are 36 funds or institutions reporting positions in Calliditas Therapeutics AB. This is an increase of 4 owner(s) or 12.50% in the last quarter. Average portfolio weight of all funds dedicated to CALT is 0.03%, an increase of 4.24%. Total shares owned by institutions increased in the last three months by 0.53% to 1,348K shares. The put/call ratio of CALT is 1.08, indicating a bearish outlook.

What are Other Shareholders Doing?

Bvf holds 750K shares representing 1.40% ownership of the company. No change in the last quarter.

IEFA - iShares Core MSCI EAFE ETF holds 205K shares representing 0.38% ownership of the company. In it's prior filing, the firm reported owning 200K shares, representing an increase of 2.34%. The firm decreased its portfolio allocation in CALT by 4.41% over the last quarter.

SCZ - iShares MSCI EAFE Small-Cap ETF holds 177K shares representing 0.33% ownership of the company. In it's prior filing, the firm reported owning 152K shares, representing an increase of 14.08%. The firm increased its portfolio allocation in CALT by 22.20% over the last quarter.

Deutsche Bank Ag\ holds 51K shares representing 0.09% ownership of the company. In it's prior filing, the firm reported owning 91K shares, representing a decrease of 79.13%. The firm decreased its portfolio allocation in CALT by 37.83% over the last quarter.

QCSTRX - Stock Account Class R1 holds 35K shares representing 0.06% ownership of the company. In it's prior filing, the firm reported owning 26K shares, representing an increase of 25.87%. The firm increased its portfolio allocation in CALT by 58.17% over the last quarter.

Calliditas Therapeutics AB Background Information
(This description is provided by the company.)

Calliditas is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.